Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
BCAX reports the sale of 16,300 shares of common stock under Rule 144, associated with the exercise of stock options and processed through UBS Financial Services on
Separately, the filing shows a prior sale of 200 shares by David Raben on
BCAX submitted a Form 144 reporting a proposed sale of 13,555 common shares to be sold on
The filing also discloses prior sales by the reporting person: 9,200 shares on
Ryan Cohlhepp filed a Form 144 reporting sales of Common stock of BCAX. The filing lists multiple dispositions in the past three months with dates, share counts, and aggregate sale amounts. Transactions include 12/15/2025: 12,500 shares for $233,547.50, 01/15/2026: 149 shares for $2,684.98, 01/22/2026: 3,828 shares for $69,295.99, and 02/25/2026: 3,631 shares for $69,132.42.
The filing also shows exercises of stock options settled in cash with issuer deliveries: 05/12/2024: 4,500 shares and 03/03/2026: 12,892 shares. The broker listed is UBS Financial Services, Inc.
RA Capital Management and affiliates report a significant ownership position in Bicara Therapeutics Inc. common stock. The reporting group, including RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., reports beneficial ownership of 7,279,739 shares, representing 11.5% of Bicara’s common stock.
The Fund directly holds 4,603,418 shares, or 7.3% of the class. On February 26, 2026, the Fund bought 300,000 shares at $16.00 per share and 2,200,000 pre-funded warrants at $15.9999 each in Bicara’s February 2026 offering, for a total of $39,999,780 funded from its working capital.
The pre-funded warrants give the Fund the right to acquire 2,200,000 shares but include a 9.99% beneficial ownership blocker, so they cannot be exercised if doing so would push the Fund and its affiliates above that ownership threshold. Ownership percentages are based on 54,781,950 shares outstanding as of November 5, 2025 plus 8,581,250 shares issued in the February 2026 offering, and include certain exercisable stock options.
Bicara Therapeutics Inc. reported insider purchases by RA Capital–affiliated funds. On February 26, 2026, entities managed by RA Capital Management, L.P. bought 2,200,000 Pre-Funded Warrants at $15.9999 per right and 300,000 shares of common stock at $16.00 per share in open-market or private transactions.
The Pre-Funded Warrants have no expiration date and are exercisable at any time after issuance, but cannot be exercised if the holder and its affiliates would own more than 9.99% of outstanding common stock after exercise. The RA Capital adviser, its general partner, the funds, and principals Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership except to the extent of their pecuniary interests.
Bicara Therapeutics Inc. director and President/COO Ryan Cohlhepp reported a set of transactions on common stock tied to stock options. He exercised stock options for 3,108 shares of common stock at an exercise price of
Bicara Therapeutics Inc. completed an underwritten equity offering combining common stock and pre-funded warrants. The company sold 7,175,000 common shares and pre-funded warrants to purchase up to 2,200,000 shares, with underwriters also exercising a 1,406,250-share option in full. Net proceeds were approximately $161.8 million, all to the company.
Bicara plans to use the cash to build medical and commercial infrastructure for a planned U.S. regulatory filing and potential launch of ficerafusp alfa, advance development in first-line HPV-negative head and neck cancer, fund manufacturing and signal-finding for indication expansion, and for general corporate purposes. The company also reported preliminary, unaudited cash, cash equivalents and investments of about $414.8 million as of December 31, 2025.
Bicara Therapeutics is offering 7,175,000 shares of common stock and pre-funded warrants to purchase up to 2,200,000 shares in a registered offering at a public offering price of
Proceeds are intended to support regulatory filing and potential U.S. commercial launch for ficerafusp alfa, accelerate development in 1L R/M HPV-negative HNSCC including a less frequent dosing schedule, fund manufacturing and early signal-finding, and for general corporate purposes. As of
Ryan Cohlhepp reported sales of common stock of BCAX on Form 144.
The filing lists three reported sales: 12/15/2025 of 12,500 shares for $233,547.50; 01/15/2026 of 149 shares for $2,684.98; and 01/22/2026 of 3,828 shares for $69,295.99.
The excerpt also lists securities to be sold via exercise of stock options: 523 shares on 05/12/2024 and 3,108 shares on 02/25/2026.